Creative medical technology holdings announces positive initial safety, tolerability, and efficacy data from first cohort in phase 1/2 trial of celz-201-ddt for chronic back pain

Phoenix, jan. 30, 2025 (globe newswire) -- creative medical technology holdings, inc. (nasdaq: celz), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising initial data from the first cohort of its ongoing phase 1/2 clinical trial of celz-201-ddt, the company's proprietary stem cell-based therapeutic for the treatment of chronic back pain caused by degenerative disc disease (ddd).
CELZ Ratings Summary
CELZ Quant Ranking